Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Tissue MicroArray (TMA) analysis of normal and persistent Chlamydophila pneumoniae infection.
PMID 17052347 · PMC1622754 · BMC infectious diseases · 2006 · 8 claims · 4 setups
TMA/IHC staining patterns of GroEL, GroES, GspD, Ndk and Pyk in cell pellets generally corresponded to differential regulation patterns previously found by 2D gel proteomic analysis of IFN-γ-induced persistence
-
Full-text index only
The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
PMID 19756916 · PMC2778706 · Targeted oncology · 2009 · 8 claims · 5 setups
Genomic/gene expression profiling alone is insufficient to identify tumors with molecular pathway changes predictive of treatment outcome; protein-level functional assessment (activation states, PTMs, interactions) is also required
-
Full-text index only
Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours.
PMID 17299397 · PMC2360083 · British journal of cancer · 2007 · 8 claims · 5 setups
A combined VEGF-A ligand and flt-1 receptor protein expression signature discriminates malignant from benign GIST
-
Full-text index only
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.
PMID 19956606 · PMC2779485 · PloS one · 2009 · 8 claims · 7 setups
A 100-gene signature from LSL-KrasG12D;Trp53Flox/Flox mouse sarcomas (vs normal muscle) is specifically and significantly enriched in human MFH but not other soft tissue sarcoma subtypes across three independent human datasets.
-
Has reproduction · 59
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
PMID 33086062 · PMC7649750 · Cell reports · 2020 · 8 claims · 8 setups
KMT2D is a potent tumor suppressor in melanoma